Holen Sie sich die Stockscreener-App
6.81
2.58%
-0.18
Handel nachbörslich:
6.80
-0.010
-0.15%
Schlusskurs vom Vortag:
$6.99
Offen:
$6.99
24-Stunden-Volumen:
1.50M
Relative Volume:
1.46
Marktkapitalisierung:
$421.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.40M
KGV:
-2.0763
EPS:
-3.2799
Netto-Cashflow:
$-151.53M
1W Leistung:
-4.49%
1M Leistung:
-22.96%
6M Leistung:
-13.47%
1J Leistung:
+7.24%
1-Tages-Spanne:
$6.6201
$7.015
1-Wochen-Bereich:
$6.6201
$7.92
52-Wochen-Spanne:
$5.30
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Firmenname
Kyverna Therapeutics Inc
Sektor
Branche
Telefon
(510) 626-8331
Adresse
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
6.81 | 421.15M | 0 | -156.40M | -151.53M | -3.2799 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-05-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-04 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten
Kyverna's miv-cel shows durable one-year benefit in stiff person syndrome and myasthenia gravis - The Pharma Letter
H.C. Wainwright reiterates Kyverna stock rating on durability data By Investing.com - Investing.com Nigeria
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG TrialsSlideshow (NASDAQ:KYTX) 2026-09-24 - Seeking Alpha
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price - TradingView
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions - Benzinga
Kyverna Shooting for Complete BLA Submission for Stiff Person Syndrome CAR T-Cell Therapy This Year - GenomeWeb
Kyverna stock jumps on positive one-year therapy data By Investing.com - Investing.com Canada
Kyverna stock jumps on positive one-year therapy data - Yahoo Finance
Kyverna’s Miv-cel Holds One-Year Benefit in Stiff Person Syndrome - Minichart
KYTX: Miv-cel delivers durable, drug-free remissions in SPS and gMG with a strong safety profile - TradingView
William Blair Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
Form 8K Kyverna Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
Why is Kyverna Therapeutics stock surging today? By Investing.com - Investing.com Canada
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials - Yahoo Finance
Kyverna reports one-year data for autoimmune CAR T therapy - Investing.com
Kyverna reports one-year data for autoimmune CAR T therapy By Investing.com - Investing.com Canada
Kyverna Therapeutics Reports Durable One-Year SPS and Up to 1.5-Year gMG Data for Miv-Cel - Quiver Quantitative
Kyverna Therapeutics reports positive one-year miv-cel data in SPS; rolling BLA on track for Q4 - TradingView
Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T - Endpoints News
Electra's IPO Break, Three CAR-T Deaths, and a Tariff Deadline Nobody Understands - finance.biggo.com
KYTX: Miv-cel shows transformative results in SPS and gMG, with regulatory and commercial milestones ahead - TradingView
Kyverna Therapeutics aims for first approved ce... - Pluang
Kyverna at Morgan Stanley healthcare conference: first autoimmune CAR T launch - Investing.com Australia
Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com Canada
KYTX: Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027 - TradingView
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BlackRock Inc. Purchases Shares of 3,134,807 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Kyverna Therapeutics (KYTX) Slips 3.08% to $8.35 as Clinical-Stage Biotech Faces Selling PressureElliott Wave Entry - dars.gov.et
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - The Globe and Mail
Kyverna Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts - BioPharma Dive
Wells Fargo Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Kyverna (KYTX): Posts a 3.09% Loss to $8.16 at the Close; Chart Watch: the Session Ends Within the Reported Technical Boundaries in the Latest SessionTime Weighted Price - dars.gov.et
Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat
Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®
Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn
Kyverna Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat
AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet
Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat
Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade
Finanzdaten der Kyverna Therapeutics Inc-Aktie (KYTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):